AtriCure (NASDAQ:ATRC) Reaches New 1-Year High – Here’s Why

Shares of AtriCure, Inc. (NASDAQ:ATRC) reached a new 52-week high on Monday . The stock traded as high as $49.98 and last traded at $47.78, with a volume of 390633 shares traded. The stock had previously closed at $48.54.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on ATRC shares. Weiss Ratings raised shares of AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 19th. Piper Sandler lifted their price target on shares of AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday. UBS Group dropped their price objective on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Raymond James Financial set a $52.00 price objective on AtriCure in a report on Tuesday, July 21st. Finally, Canaccord Genuity Group raised their target price on AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $49.89.

AtriCure Stock Performance

The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The company has a market cap of $2.39 billion, a PE ratio of 223.09 and a beta of 1.20. The business’s 50-day moving average is $37.89 and its 200 day moving average is $32.22.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The firm had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same quarter in the previous year, the company posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities research analysts predict that AtriCure, Inc. will post 0.29 EPS for the current fiscal year.

Insider Activity at AtriCure

In other AtriCure news, Director Maggie Yuen sold 3,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $38.42, for a total transaction of $134,470.00. Following the completion of the transaction, the director owned 14,015 shares of the company’s stock, valued at $538,456.30. This represents a 19.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Sven Wehrwein sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total value of $946,000.00. Following the transaction, the director directly owned 40,518 shares of the company’s stock, valued at $1,533,201.12. The trade was a 38.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 53,616 shares of company stock valued at $2,149,994 in the last quarter. 4.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On AtriCure

Several hedge funds have recently made changes to their positions in ATRC. Smartleaf Asset Management LLC grew its position in shares of AtriCure by 59.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after buying an additional 429 shares during the period. Scotia Capital Inc. lifted its position in AtriCure by 1.2% during the 3rd quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock valued at $1,328,000 after acquiring an additional 457 shares during the period. ProShare Advisors LLC lifted its position in AtriCure by 6.6% during the 4th quarter. ProShare Advisors LLC now owns 8,819 shares of the medical device company’s stock valued at $349,000 after acquiring an additional 543 shares during the period. Captrust Financial Advisors boosted its stake in AtriCure by 7.9% during the fourth quarter. Captrust Financial Advisors now owns 7,944 shares of the medical device company’s stock worth $314,000 after acquiring an additional 579 shares in the last quarter. Finally, Mackenzie Financial Corp boosted its stake in AtriCure by 5.3% during the fourth quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company’s stock worth $545,000 after acquiring an additional 683 shares in the last quarter. 99.11% of the stock is owned by hedge funds and other institutional investors.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.